Source-grounded facts extracted from ARROWHEAD PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dr. Matt Cohen was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
“On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.”
ARROWHEAD PHARMACEUTICALS, INC. reported financial results for fiscal 2026 second quarter ended March 31, 2026.
“Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.”
ARROWHEAD PHARMACEUTICALS, INC. entered into underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC as representatives of the several underwriters valued at an additional $75,000,000 aggregate principal amount of Notes (effective 2026-01-12).
“Pursuant to an underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Underwriters”), the Company granted the Underwriters an option, which is exercisable within 30 days after January 7, 2026, to purchase up to an additional $75,000,000 aggregate principal amount of Notes solely to cover over-allotments.”
ARROWHEAD PHARMACEUTICALS, INC. entered into Indenture with U.S. Bank Trust Company, National Association valued at $700,000,000 aggregate principal amount (effective 2026-01-12).
“On January 12, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) issued $700,000,000 aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of January 12, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture”
ARROWHEAD PHARMACEUTICALS, INC. entered into Convertible Notes Underwriting Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters valued at $625,000,000 aggregate principal amount (effective 2026-01-07).
“On January 7, 2026, the Company entered into an underwriting agreement (the “Convertible Notes Underwriting Agreement”) with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Convertible Notes Underwriters”), to issue and sell (the “Convertible Notes Offering”) $625,000,000 aggregate principal amount of its 0.00% convertible senior notes due 2032”
ARROWHEAD PHARMACEUTICALS, INC. entered into Equity Underwriting Agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters (effective 2026-01-07).
“On January 7, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Equity Underwriters”), to issue and sell 3,100,776 shares of the Company’s common stock”
Daniel Apel was appointed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
“the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company”
Ken Myszkowski departed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
“Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025”
Douglas Ingram was appointed as director at ARROWHEAD PHARMACEUTICALS, INC..
“On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.”
ARROWHEAD PHARMACEUTICALS, INC. reported Fiscal 2024 second quarter (three months ended March 31, 2024) results: net income Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300), EPS Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02).
“OPERATING SUMMARY 2024 2023 (Unaudited) Revenue $ — $ 146,267 Operating Expenses: Research and development 101,122 74,881 General and administrative expenses 25,069 23,221 Total Operating Expenses 126,191 98,102 Operating (loss) income (126,191) 48,165 Total other expense (805) (489) (Loss) income before income tax expense and noncontrolling interest (126,996) 47,676 Income tax expense — — Net (loss) income including noncontrolling interest (126,996) 47,676 Net (loss) income attributable to noncontrolling interest, net of tax (1,696) (999) Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300) $ 48,675 Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02) $ 0.45”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Ratification of KPMG as independent auditors. at the 2024-03-14 meeting.
“Ratification of KPMG as Independent Auditors of the Company 104,057,945 FOR 2,562,563 AGAINST 365,912 ABSTAIN 0 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation. at the 2024-03-14 meeting.
“Advisory Vote to Approve Executive Compensation 82,576,047 FOR 4,950,419 AGAINST 143,385 ABSTAIN 19,316,569 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Election of seven directors to serve until next annual meeting. at the 2024-03-14 meeting.
“Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 76,397,567 10,968,346 303,938 19,316,569 Michael S. Perry 82,446,900 4,911,855 311,096 19,316,569 Christopher Anzalone 84,313,696 2,976,660 379,495 19,316,569 Mauro Ferrari 81,342,884 6,020,799 306,168 19,316,569 Adeoye Olukoton 83,526,809 3,815,731 327,311 19,316,569 William Waddill 83,279,633 4,079,251 310,967 19,316,569 Victoria Vakiener 83,354,988 3,975,617 339,246 19,316,569”
Hongbo Lu was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
“Appointment of Hongbo Lu as a Director”
Hongbo Lu was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
“On February 21, 2024, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) announced that it would increase the size of the Company's board of directors ("Board") from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024.”
ARROWHEAD PHARMACEUTICALS, INC. reported fiscal 2024 first quarter ended December 31, 2023 results: revenue $ 3,551, net income $ (132,864), EPS $ (1.24).
“INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2023 2022 (Unaudited) Revenue $ 3,551 $ 62,546 Operating Expenses: Research and development 116,491 83,695 General and administrative expenses 23,605 20,985 Total Operating Expenses 140,096 104,680 Operating loss”
Bruce Given was appointed as Chief Medical Scientist at ARROWHEAD PHARMACEUTICALS, INC..
“Bruce Given, M.D., who previously served as the Company's Chief Operating Officer and head of Research and Development until his retirement on May 1, 2020, will assist the Company in the orderly transition of Dr. San Martin's departure in Dr. Given’s new role as Chief Medical Scientist.”
Javier San Martin departed as Chief Medical Officer at ARROWHEAD PHARMACEUTICALS, INC..
“Javier San Martin, M.D., the Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (the “Company”), will be leaving the Company, effective as of February 1, 2024.”
ARROWHEAD PHARMACEUTICALS, INC. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $429.0 million (effective 2024-01-02).
“On January 2, 2024, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 15,790,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share at an offering price of $28.50 per Share (the “Offering”).”
ARROWHEAD PHARMACEUTICALS, INC. engaged KPMG, LLP as its auditor.
“On December 01, 2023, the Audit Committee recommended, and the Board of Directors of the Company approved, the engagement of KPMG, LLP ("KPMG") as the Company's new independent registered public accounting firm for the Company's fiscal year ending September 30, 2024.”
ARROWHEAD PHARMACEUTICALS, INC. dismissed Rose, Snyder & Jacobs, LLP as its auditor.
“On December 01, 2023, the Audit Committee of the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the "Company") approved the dismissal of Rose, Snyder & Jacobs, LLP ("RSJ") as the Company's independent registered public accounting firm, effective immediately.”
ARROWHEAD PHARMACEUTICALS, INC. reported fiscal year ended September 30, 2023 results: revenue $ 240,735, net income $ (205,275), EPS $ (1.92).
“PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended September 30, OPERATING SUMMARY 2023 2022 Revenue $ 240,735 $ 243,231 Operating Expenses: Research and development 353,188 297,307 General and administrative expenses 92,549 124,431 Total Operating Expenses 445,737 421,738 Operating loss”
ARROWHEAD PHARMACEUTICALS, INC. reported its fiscal second quarter ended March 31, 2023 results: revenue $ 146,267, net income $ 48,675, EPS $ 0.45.
“in The New England Journal of Medicine Selected Fiscal 2023 Second Quarter Financial Results Three Months Ended March 31, OPERATING SUMMARY 2023 2022 (unaudited) Revenue $ 146,267 $ 151,805 Operating Expenses: Research and development 74,881 75,985 General and administrative expenses 23,221 34,267 Total Operating Expenses 98,102 110,252 Operating income”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Ratification of Rose, Snyder & Jacobs as independent auditors at the 2023-03-16 meeting.
“Ratification of Rose, Snyder & Jacobs as Independent Auditors of the Company 86,613,251 FOR 1,296,520 AGAINST 863,437 ABSTAIN 0 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Approval of amendment to increase authorized shares of common stock at the 2023-03-16 meeting.
“Approval of Amendment to Increase Authorized Shares of Common Stock 80,352,213 FOR 8,279,373 AGAINST 141,622 ABSTAIN 0 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation at the 2023-03-16 meeting.
“Advisory Vote to Approve Executive Compensation 62,683,718 FOR 7,119,440 AGAINST 280,607 ABSTAIN 18,689,443 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Election of eight directors to serve until next annual meeting at the 2023-03-16 meeting.
“Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 67,160,632 2,517,893 405,240 18,689,443 Michael S. Perry 65,416,779 4,172,284 494,702 18,689,443 Christopher Anzalone 67,517,726 2,257,619 308,420 18,689,443 Marianne De Backer 64,099,823 5,531,033 452,909 18,689,443 Mauro Ferrari 62,760,154 6,726,045 597,566 18,689,443 Adeoye Olukoton 65,203,181 4,295,706 584,878 18,689,443 William Waddill 63,143,044 6,415,395 525,326 18,689,443 Victoria Vakiener 67,756,449 1,797,645 529,671 18,689,443”
ARROWHEAD PHARMACEUTICALS, INC. terminated Collaboration Agreement with Janssen Pharmaceuticals, Inc. (effective 2023-04-07).
“On February 10, 2023, Arrowhead Pharmaceuticals, Inc. (the “Company”) received notice from Janssen Pharmaceuticals, Inc. (“Janssen”) that Janssen has elected to terminate the Research Collaboration and Option Agreement between the Company and Janssen, dated October 3, 2018 (as amended by Amendment No. 1 to the Research Collaboration and Option Agreement between the Company and Janssen, dated as of November 14, 2019, the “Collaboration Agreement”).”
Marianne De Backer resigned as director at ARROWHEAD PHARMACEUTICALS, INC..
“On February 11, 2023, Marianne De Backer , a director of Arrowhead Pharmaceuticals, Inc. (the “Company”), notified the Company of her decision to resign as a director, effective as of April 2, 2023.”
ARROWHEAD PHARMACEUTICALS, INC. reported first quarter ended December 31, 2022 results: revenue $62,546, net income ($41,325), EPS $(0.39).
“INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2022 2021 (unaudited) Revenue $ 62,546 $ 27,439 Operating Expenses: Research and development 83,695 65,765 General and administrative expenses 20,985 24,995 Total Operating Expenses 104,680 90,760 Operating loss”
ARROWHEAD PHARMACEUTICALS, INC.: Amended and restated bylaws with updates including proxy access provisions, procedural mechanics, and conforming changes (effective 2023-01-24).
“On January 24, 2023, the Board of Directors (the “Board”) of Arrowhead Pharmaceuticals, Inc. (the “Company”) amended and restated the Company's Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”), which became effective immediately.”
ARROWHEAD PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at approximately $250 million (effective 2022-12-02).
“On December 2, 2022, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an open market sale agreement (the “Open Market Sale Agreement”) with Jefferies LLC (the "Agent"), pursuant to which the Company agreed to issue and sell up to 7,807,620 shares of common stock (the “Shares”), par value $0.001 per share (the “Common Stock”). The Company estimates that gross proceeds from the offering will be approximately $250 million”
ARROWHEAD PHARMACEUTICALS, INC. entered into Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at up to $410 million (effective 2022-11-09).
“Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into a Royalty Purchase Agreement (the “Purchase Agreement”) with Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), pursuant to which Royalty Pharma agreed to pay up to $410 million in cash to the Company”
Patrick O'Brien was appointed as Chief Operating Officer and General Counsel at ARROWHEAD PHARMACEUTICALS, INC..
“Arrowhead Pharmaceuticals, Inc. (the “Company”) has appointed Patrick O’Brien, age 59, as Chief Operating Officer and General Counsel effective as of July 15, 2022.”
Victoria Vakiener was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
“the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Victoria Vakiener as an independent director of the Company effective May 2, 2022.”
James Hassard departed as Chief Commercial Officer at ARROWHEAD PHARMACEUTICALS, INC..
“Effective August 23, 2021, James Hassard, the former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. (the “Company”) is no longer with the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.